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activate murine and all human STING
alleles as a therapeutic. Intratumoral
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systemic immune responses, mediating
rejection of distant metastases and
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Spontaneous tumor-initiated T cell priming is depen-
dent on IFN-b production by tumor-resident den-
dritic cells. On the basis of recent observations indi-
cating that IFN-b expression was dependent upon
activation of the host STING pathway, we hypothe-
sized that direct engagement of STING through intra-
tumoral (IT) administration of specific agonists would
result in effective anti-tumor therapy. After proof-of-
principle studies using the mouse STING agonist
DMXAA showed a potent therapeutic effect, we
generated synthetic cyclic dinucleotide (CDN) de-
rivatives that activated all human STING alleles as
well as murine STING. IT injection of STING agonists
induced profound regression of established tumors
in mice and generated substantial systemic immune
responses capable of rejecting distant metastases
and providing long-lived immunologic memory. Syn-
thetic CDNs have high translational potential as a
cancer therapeutic.INTRODUCTION
The responsiveness of tumors to immunotherapy depends, at
least in part, on the immunophenotype of the tumor microenvi-
ronment (TME) (Gajewski et al., 2013). Substantial evidence indi-
cates that tumor-infiltrating lymphocytes (TILs) are correlated
with favorable prognosis in diverse malignancies (Galon et al.,
2012) and predicts a positive clinical outcome in response to
several immunotherapy strategies (Postow et al., 2012; Wolchok
et al., 2013). Understanding the underlying mechanisms that
promote spontaneous T cell infiltration is critical toward devel-
oping new therapeutic strategies that can be used to effectively
promote an immune-responsive TME.
Innate immune sensing in the TME is a critical step in promot-
ing spontaneous tumor-initiated T cell priming and subsequent1018 Cell Reports 11, 1018–1030, May 19, 2015 ª2015 The AuthorsTIL infiltration (Fuertes et al., 2011). Transcriptional profiling an-
alyses of melanoma patients have revealed that tumors contain-
ing infiltrating activated T cells are characterized by a type I IFN
transcriptional signature (Harlin et al., 2009). Studies in mice
have demonstrated that type I IFN signaling plays a critical role
in tumor-initiated T cell priming (Diamond et al., 2011; Fuertes
et al., 2011). Mice lacking the IFN-a/b receptor in DCs cannot
reject immunogenic tumors, and CD8a+ DCs from these mice
are defective in antigen cross-presentation to CD8+ T cells.
Furthermore, Baft3/ mice that lack the CD8a+ DC lineage
lose the capacity to spontaneously prime tumor-specific CD8+
T cells (Fuertes et al., 2011; Hildner et al., 2008). These findings
in humans and in mice indicate that the tumor-resident antigen-
presenting cell (APC) compartment is defective in non-T-cell-in-
flamed tumors. Thus, strategies to induce type I IFN signaling
and APC activation in the TME to bridge the innate and adaptive
immune responses may have therapeutic utility.
Recent work has demonstrated that activation of the STING
pathway in tumor-resident host APCs is required for induction
of a spontaneous CD8+ T cell response against tumor-derived
antigens in vivo (Woo et al., 2014). In addition, activation of this
pathway and the subsequent production of IFN-b contributes
to the anti-tumor effect of radiation (Deng et al., 2014), which
can be potentiated with co-administration of a natural STING
agonist. STING (stimulator of interferon genes, also known as
TMEM173, MITA, ERIS, and MPYS) is a transmembrane protein
localized to the ER that undergoes a conformational change in
response to direct binding of cyclic dinucleotides (CDNs), result-
ing in a downstream signaling cascade involving TBK1 activa-
tion, IRF-3 phosphorylation, and production of IFN-b and other
cytokines (Burdette et al., 2011; Burdette and Vance, 2013; Ishi-
kawa and Barber, 2008). IFN-b is the signature cytokine induced
in response to activating STING, by either exogenous CDNs pro-
duced by bacterial infection or through binding of a structurally
distinct endogenous CDN produced by a host cyclic GMP-
AMP synthetase (cGAS) in response to sensing cytosolic dou-
ble-stranded DNA (dsDNA) (Ablasser et al., 2013; Diner et al.,
2013; McWhirter et al., 2009; Sun et al., 2013; Woodward
et al., 2010; Zhang et al., 2013). These observations suggested
that direct activation of the STING pathway in the TME by intra-
tumoral (IT) injection of specific agonists might be an effective
therapeutic strategy to promote broad tumor-initiated T cell
priming against an individual’s tumor antigen repertoire.
To test this therapeutic approach, we began with 5,6-dime-
thylxanthenone-4-acetic acid (DMXAA), a defined flavonoid
compound known as a vascular disrupting agent that was shown
to have anti-tumor activity in mouse models (Baguley and Ching,
1997). This drug ultimately failed in humans when combined with
standard-of-care chemotherapy in a phase 3 efficacy trial in non-
small-cell lung cancer (Lara et al., 2011). Interestingly, recent
structure-function studies of mouse STING (mSTING) and hu-
man STING (hSTING) demonstrated that DMXAA is a direct
ligand for mSTING (Conlon et al., 2013; Gao et al., 2013a; Kim
et al., 2013; Prantner et al., 2012). However, detailed analysis re-
vealed that polymorphisms in hSTING rendered it unable to bind
DMXAA, therefore abrogating its activity in human cells. These
findings provide a mechanistic insight for the lack of DMXAA ef-
ficacy in humans as well as the rationale for the development of
new pharmacologic compounds that potently activate hSTING.
Whereas STING agonists are being developed as vaccine adju-
vants (Dubensky et al., 2013; Ebensen et al., 2011; Gray et al.,
2012), whether STING agonists could have direct anti-tumor
therapeutic effects has been under-explored and the lack of
defined agonists that could activate all known hSTING alleles
has been lacking.
In the current report, we confirm that DMXAA is a strong
agonist of the mSTING pathway in vitro and in vivo. We
show that IT injection of DMXAA effectively primes CD8+ T cell
responses to promote rejection of established tumors in a
STING-dependent fashion. Based on these proof-of-concept re-
sults, we synthesized a large panel of CDNs and selected com-
pounds capable of activating all known hSTING alleles. Unlike
DMXAA, selected compounds indeed stimulated human PBMCs
to produce IFN-b. Like DMXAA, these STING agonists exhibit
significant anti-tumor efficacy in several mouse tumor models,
without significant local or systemic toxicity. Strikingly, direct
IT injection of selected CDNs into established B16 melanoma,
CT26 colon, and 4T1 breast carcinomas resulted in rapid and
profound tumor regression and promoted lasting systemic anti-
gen-specific T cell immunity. These effects were entirely STING-
dependent and resulted in regression of non-injected tumors in
the same hosts. We selected dithio-(RP, RP)-[cyclic[A(2
0,50)
pA(30,50)p]], (ML RR-S2 CDA) as the lead molecule for continued
development. This agent has high translational potential as a
therapeutic intervention strategy to induce activation of the
TME in multiple tumor types, with the mechanistic goal of gener-
ating effective tumor-initiated CD8+ T cell priming and lasting
anti-tumor efficacy.
RESULTS
DMXAA Stimulates the STING Pathway In Vitro
We first confirmed that DMXAA was a functional agonist of the
STING pathway using mouse macrophages in vitro. STING ag-
gregation was assessed using STING/macrophages express-
ing mSTING-HA. Control macrophages presented a diffuse
pattern of STING in the cytoplasm, but after 1 hr of incubationCwith DMXAA, approximately 60% of cells displayed aggregates
of STING in perinuclear sites (Figure 1A). Downstream phosphor-
ylation of TBK1 and IRF3 was observed, which was abolished in
STING/ cells (Figure 1B). This correlated with an increase in
the apparent molecular weight of STING, which has been re-
ported to be due to its phosphorylation (Konno et al., 2013).
STING/macrophages reconstituted withmSTING-HA showed
restored phosphorylation of TBK1 and IRF3. IFN-b secretion was
detected from wild-type (WT), but not from STING/, macro-
phages in response to DMXAA (Figure 1C). Similar results were
observed with bone-marrow-derived DCs (BM-DC) from WT
versus STING/ mice (Figures S1A and S1B). We also used
BM-DCs cells to study the expression of additional immunoreg-
ulatory molecules. IFN-b, IFN-a, TNF-a, IL-1b, IL-6, and IL12p40
were induced after stimulation with DMXAA in WT cells, but not
STING/ BM-DCs (Figure S1C). Whereas LPS induced expres-
sion of CD40, PD-L1, CD86, and MHC class II in both WT and
STING-deficient DCs, induction with DMXAA was observed
only in WT cells (Figures S1D and S1E). Together, these data
along with previous studies (Conlon et al., 2013; Gao et al.,
2013a; Kim et al., 2013; Prantner et al., 2012) confirm that
DMXAA is a strong agonist of mSTING, resulting in the produc-
tion of IFN-b and other innate cytokines and activation of DCs.
DMXAA Induces Strong Anti-tumor Immunity In Vivo
In order to evaluate whether stimulation of STING could augment
anti-tumor immunity in vivo, we chose an IT route of administra-
tion to focus activation on those APCs acquiring tumor antigens.
To assess an antigen-specific immune response, we utilized the
B16melanoma cell line transduced to express themodel antigen
SIYRYYGL (B16.SIY) (Blank et al., 2004). B16.SIY tumor cells
were inoculated into the flank of WT or STING-deficient mice
and injected IT with DMXAA at day 7. The dose of 500 mg of
DMXAA was chosen after examining single doses ranging from
150 to 625 mg, with the highest dose of 625 mg showing unac-
ceptable toxicity (data not shown). In WT animals, the selected
dosage induced potent tumor regression and complete tumor
rejection in the majority of mice; however, no reduction in tumor
growth was observed in response to DMXAA in the absence of
host STING (Figure 2A). Analysis of splenocytes 5 days after
treatment showed a marked increase in the frequency of SIY-
specific IFN-g-producing T cells inWTmice, but not in STING/
mice (Figure 2B). Similarly, treatment with DMXAA caused a high
frequency of SIY-specific CD8+ T cells detected by SIY/Kb pen-
tamer staining in WT animals, but not in STING-deficient mice
(Figure 2C). Next, we examined whether DMXAA treatment had
any effect in animals deficient in the type I IFN receptor (IFNAR).
A significant portion of the anti-tumor effect of DMXAA was lost
in IFNAR-deficient mice, and none of the deficient animals
showed complete tumor rejection (Figure 2D).
To determine whether immunologic memory was induced, WT
mice that had rejected B16.SIY tumors were re-challenged
60 days after the initial inoculation with the same tumor cells.
None of the re-challenged animals developed tumors (Figure 2E).
We then investigated whether the anti-tumor immune response
induced following DMXAA administration could be potent
enough to reject non-injected secondary tumors. B16.SIY cells
were injected in both flanks of mice, but only one tumor wasell Reports 11, 1018–1030, May 19, 2015 ª2015 The Authors 1019
Figure 1. DMXAA Activates the STING Pathway and Promotes the Activation of APCs
(A) STING/mouse bone-marrow-derivedmacrophages (BMM) transduced to express STING-HA tagwere stimulated for 1 hr with 50 mg/ml DMXAA and stained
with specific antibodies against HA-tag, CD11b, and DAPI. Single cell images were acquired in the ImageStream, and data were analyzed with the IDEAS
software (Amnis; Millipore). The data in the graph represent average of percentage of cells with aggregates from three independent experiments.
(B) WT or STING/BMMwere stimulatedwith 50 mg/ml of DMXAA for the indicated time points. The amount of pTBK1, total TBK1, pIRF3, total IRF3, STING, and
GAPDH was measured by western blot.
(C) WT or STING/ BMM were stimulated with 50 mg/ml of DMXAA for 12 hr. The amount of secreted IFN-b was measured by ELISA.treated with DMXAA. Tumor regression was observed in both
sites (Figure 2F), suggesting that IT DMXAA administration can
have a therapeutic effect on distant tumors. This effect was un-
likely secondary to systemic distribution of the drug, because
deliberate systemic administration of DMXAA via intraperitoneal
administration had an inferior therapeutic effect (data not
shown). These results demonstrate that a STING agonist can
activate tumor-specific immune response capable of eliminating
distal tumors and protecting from tumor challenge.
To assess whether the potent anti-tumor efficacy resulting
from IT administration of DMXAA could be broadly applied, we
tested several additional syngeneic tumor models. Treatment
with DMXAA significantly reduced the growth of B16.F10
(without expression of SIY) and TRAMPC2 tumors in C57BL/6
mice, 4T1 tumors in BALB/c mice, and Ag104L tumors in C3H
mice, indicating that the therapeutic effect of DMXAA is not
restricted to a specific tumor histology or mouse genetic back-
ground (Figures S2A–S2D).
To determine whether the adaptive immune response was
required for tumor control, B16.SIY cells were inoculated into
RAG2/ mice that lack mature T and B cells. DMXAA treatment
lost most of its therapeutic effect in RAG2/ hosts, although
there was a partial control of tumor growth (Figure S2E). A similar
loss of therapeutic effect was observed in TCRa/ mice (Fig-
ure S2F) and in mice depleted of CD8+ T cells (Figure S2G),
but not in mice depleted of CD4+ T cells or NK cells (Figures
S2H and S2I). These results indicate that a significant compo-1020 Cell Reports 11, 1018–1030, May 19, 2015 ª2015 The Authorsnent of the therapeutic effect of DMXAA is mediated by CD8+
T cells.
Identification of Synthetic hSTING-Activating Molecules
Having shown that the STING pathway could be harnessed to
promote tumor antigen-specific CD8+ T cell priming, leading to
significant therapeutic efficacy, we sought to identify com-
pounds that could potently activate hSTING and therefore be
considered for clinical translation. CDNs have been studied as
small-molecule second messengers synthesized by bacteria,
which regulate diverse processes including motility and forma-
tion of biofilms (Ro¨mling et al., 2013). The immunogenicity of re-
combinant protein antigens can be augmented with CDNs used
as an adjuvant, giving CDNs a potential application toward vac-
cine development (Dubensky et al., 2013; Ebensen et al., 2007a,
2007b, 2011; Gray et al., 2012). We sought to develop synthetic
CDN compounds with increased activity in human cells as well
as the ability to engage all known polymorphic hSTING mole-
cules. The availability of CDN-STING crystal structures, along
with recent results describing hSTING allele/CDN-dependent
signaling relationships, facilitated structure-based studies to
design CDN compounds with increased activity. We synthesized
compounds that varied in purine nucleotide base, structure of
the phosphate bridge linkage, and substitution of the non-
bridging oxygen atoms at the phosphate bridge with sulfur
atoms. Native CDN molecules are sensitive to degradation by
phosphodiesterases that are present in host cells or in the
Figure 2. Rejection of Tumors in Response to DMXAA Is STING Dependent
(A) WT or STING/C57BL/6mice were inoculated with 106 B16.SIY cells in the left flank.When tumor volumes were 100–200mm3, they received a single IT dose
of 500 mg of DMXAA or saline. Tumor volume was measured at the indicated time points (n = 5).
(B and C) WT or STING/ C57BL/6 mice (n = 5) were treated as in (A), and 5 days later, splenocytes were harvested and re-stimulated in vitro in the presence of
culturemedium or soluble SIY peptide for 16 hr. The frequency of tumor-specific IFN-g-producing cells was assessed by ELISPOT (B), and the percentage of SIY-
specific CD8+ T cells was assessed by staining splenocytes with antibodies against TCRb, CD4, CD8, and SIY pentamer (C). Cells were acquired in the LSRII-Blue
cytometer and analyzed with FlowJo software. Results are shown as mean ± SEM. *p < 0.05; **p < 0.01.
(D) WT or IFNAR/C57BL/6 mice were inoculated with 106 B16.SIY cells in the left flank (n = 5). When tumor volumes were 100–200 mm3, they received a single
IT dose of 500 mg of DMXAA or saline. Tumor volume was measured at the indicated time points.
(E) WT mice that had rejected B16.SIY tumors were re-challenged with 106 B16.SIY in the contralateral flank. Naive mice were used as controls. Tumor size was
measured at the indicated time points.
(F) WTmice were inoculated with 106 B16.SIY cells in the left and the right flanks (n = 5). When tumor volumes were 100–200mm3, 500 mg of DMXAA or saline was
injected IT in the right flank only and tumor volume was measured at the indicated time points. Data are representative of at least three independent experiments
or two independent experiments for the contralateral tumor model. Results are shown as mean tumor volume ± SEM. *p < 0.5; **p < 0.01; ***p < 0.001. ns, not
significant.systemic circulation (Yan et al., 2008). We found thatRp, Rp (R,R)
dithio-substituted diastereomer CDNs were both resistant to
digestion with snake venom phosphodiesterase and induced
higher expression of type I IFNs in human THP-1 cells compared
to the Rp, Sp (R,S) dithio-substituted diastereomers or unmodi-
fied CDNs (data not shown).
To increase their affinity for STING, CDNs were also synthe-
sized with a phosphate bridge configuration containing both
20-50 and 30-50 linkages, termed ‘‘mixed linkage’’ (ML), as found
in endogenous human CDNs produced by cGAS (Ablasser
et al., 2013; Diner et al., 2013; Gao et al., 2013b; Wolchok
et al., 2013). The synthesis of dithio mixed-linkage CDNs, via
modifications of literature procedures (Gaffney et al., 2010), re-
sulted in bothR,R- andR,S dithio diastereomers, which were pu-
rified and separated by a combination of silica gel and C18
reverse-phase prep-HPLC chromatography, affording CDNs
withR95% purity as shown for ML RR-S2 CDA (Figure S3A, up-
per panel). The spectra for both 1H NMR (data not shown) and
the 31P NMR (y axis of Figure S3A, upper panel) were consistentCwith ML RR-S2 CDA. Direct evidence for the regiochemistry of
the phosphodiester linkages was obtained by 1H-1H COSY (cor-
relation spectroscopy for assignment of ribose protons shown
on x axis of Figure S3A, lower panel), in combination with a
1H-31P HMBC (heteronuclear multiple-bond correlation spec-
troscopy) 2D NMR (Figure S3A, lower panel). The 3D X-ray crys-
tal structure of ML RR-S2 CDA confirms the presence of the
20-50, 30-50 mixed phosphodiester linkage and a dithio [RP, RP]
diastereomer configuration (Figure S3B).
Synthetic CDNs Have Enhanced Binding Affinity to
STING and Activate All Known hSTING Alleles
We purified recombinant hSTING and evaluated the relative
binding affinity to various modified CDNs using differential scan-
ning fluorimetry (DSF). DSF measures the stability of complex
formation as a function of temperature as an indirect readout
of protein-ligand association (Cavlar et al., 2013; Niesen et al.,
2007). The increased shift in thermal stability of hSTING bound
to ML RR-S2 CDA or ML RR-S2 cGAMP relative to unmodifiedell Reports 11, 1018–1030, May 19, 2015 ª2015 The Authors 1021
(legend on next page)
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CDNs indicates that R,R dithio and ML modifications enhance
the binding affinity to STING (Figure 3A). Similar results were ob-
tained using purified mSTING (Figure S3C). It has been shown
recently that the bisphosphothionate analog of endogenous
cGAMP (ML cGAMP) is resistant to hydrolysis by ENPP1 phos-
phodiesterase and thus is more potent at inducing IFN-b secre-
tion in human THP1 cells (Li et al., 2014). Similarly, we found that
R,R dithio-modified CDA compounds (ML RR-S2 CDA and RR-
S2 CDA) showed enhanced type I IFN production over CDA in
THP-1 human monocytes (Figure S3D).
SNPs in the hSTING gene have been shown to affect the
responsiveness to bacterial-derived canonical CDNs (Diner
et al., 2013; Gao et al., 2013b). Five haplotypes of hSTING
have been identified (WT, REF, HAQ, AQ, and Q alleles), which
vary at amino acid positions 71, 230, 232, and 293 (Figure 3B)
(Jin et al., 2011; Yi et al., 2013). To test the responsiveness of
the five hSTING variants to synthetic CDNs, we created stable
HEK293T cell lines (defective in endogenous STING signaling)
expressing each of the full-length hSTING variants. Similar levels
of STING protein were expressed in each of the cell lines (Fig-
ure 3C). DMXAA potently activated mSTING and failed to acti-
vate any of the five hSTING alleles (Figure S3E), consistent
with previous studies evaluating one of the hSTING alleles (Con-
lon et al., 2013). Cells expressing hSTINGREF responded poorly
to stimulation with the bacterial CDN compounds cGAMP,
CDA, and CDG but were responsive to the endogenously pro-
duced cGAS product, ML cGAMP (Diner et al., 2013). Interest-
ingly, the hSTINGQ allele was also refractory to the bacterial
CDNs. Cells expressing mSTING were responsive to all of the
CDNs tested (Figure 3D). Cells transformed with either an empty
vector or expressing a non-functional mutant (I199N) STING pro-
tein (Goldenticket; Sauer et al., 2011) were not responsive to any
of the compounds (data not shown). In contrast, the dithio,
mixed-linkage CDN derivatives (ML RR-CDA, ML RR-S2 CDG,
and ML RR-S2 cGAMP) potently activated all five hSTING
alleles, including the refractory hSTINGREF and hSTINGQ alleles
(Figure 3D).
CDN Derivatives Potently Induce STING-Dependent
Signaling in Murine and Human Immune Cells
To determine whether modified CDNs activated downstream
STING signaling, we assessed murine bone marrow macro-
phages (BMMs) isolated fromWTC57BL/6 and STING/ (Gold-
enticket) mice (Sauer et al., 2011) for induction of IFN-b and other
cytokines. Synthetic dithio mixed-linkage CDNs (ML RR-S2 CDAFigure 3. Modified CDNs Potently Activate STING and Signal through
(A) Purified human STING binding to CDNs were analyzed by thermal shift assay.
independent experiments performed in duplicate. Tm shift values are mean valu
(B) Domain structure of hSTING is shownwith the positions of the amino acid varia
hand column were obtained from the 1000 Genome Project database as previou
(C) HEK293T cells were stably transfected with the indicated STING alleles. Who
STING-HA proteins were analyzed by western blot with anti-HA antibodies.
(D) HEK293T cells expressing the indicated STING alleles were transfected with a
with the indicated CDN compound (10 mM) and assessed for IFN-b-reporter acti
(E and F) Human PBMCs from donors with the indicated STING alleles were stim
PBMCs from a donor homozygous for the reference variant (STINGREF/REF) were s
After a 6-hr stimulation, fold induction of IFN-b was measured by qRT-PCR and
controls. Results are representative of at least two independent experiments.
Cand ML RR-S2 CDG) induced the highest expression of IFN-b
and the pro-inflammatory cytokines TNF-a, IL-6, and MCP-1
on a molar equivalent basis, as compared to endogenous ML
cGAMP and the TLR3 agonist poly I:C (Figure S4A). Themodified
CDNs did not induce signaling in STING/ BMMs, whereas, as
expected, poly I:C agonists were still active. ML RR-S2 CDAwas
also found to induce aggregation of STING and induce phos-
phorylation of TBK1 and IRF3 in mouse BMM (Figures S4B and
S4C). All of the modified CDNs tested also enhanced MHC class
II and expression of co-stimulatory markers in a STING-depen-
dent manner (Figure S4D).
To examine activation of STING signaling in primary human
cells, we stimulated PBMCs from a panel of human donors
harboring different STING alleles (hSTINGWT/WT, hSTINGWT/REF,
and hSTINGWT/HAQ) and measured induction of IFN-b. In
contrast to a lack of activation by DMXAA, dithio-modified ML
CDNs induced IFN-b expression across thesedonors (Figure 3E).
Importantly, dithio-modified ML CDNs, as well as the non-ca-
nonical cGAS product ML cGAMP, induced IFN-b expression
in a donor homozygous for the hSTINGREF allele, which was re-
fractory to stimulation with canonical CDNs in HEK293T cells
(Figures 3D and 3F). Looking at protein secretion by multiple do-
nors that are homozygous for the hSTINGWT allele, ML RR-S2
CDA induced significantly higher levels of IFN-awhen compared
to ML cGAMP (Figure S4E). Thus, ML RR-S2 CDNs are viable
clinical candidates capable of activating STING pathway in hu-
man cells harboring different STING alleles and genotypes.
Intratumoral Delivery of Synthetic CDN Derivatives
Results in Profound Anti-tumor Efficacy in Established
B16 Melanoma
To evaluate whether modified dithio ML CDN compounds
conferred increased anti-tumor activity, mice bearing estab-
lished B16.F10 tumors were treated with three IT injections of
CDN derivatives over a 1-week period. Whereas treatment with
ML CDA and ML CDG had modestly reduced tumor growth,
the R,R dithio derivatives profoundly inhibited tumor growth (Fig-
ure 4A). However, ML RR-S2 CDG was reactogenic, and these
mice developed open wounds in the treated tumor that did not
heal (data not shown). Lower dose levels of ML RR-S2 CDG
were not efficacious (data not shown), indicating that this mole-
cule had a narrow therapeutic index. In contrast, no injection site
reactogenicity was observed with ML RR-S2 CDA and several
mice developed vitiligo upon fur regrowth following complete
eradication of the treated tumor (data not shown). Importantly,All Human STING Allelic Variants
Temperature curves are the average from a representative experiment of three
es ± SEM.
tions (bottom). The allelic frequencies of the hSTING isoforms shown on the left
sly described (Yi et al., 2013).
le-cell lysates from HEK293T cells stably expressing the indicated full-length
n IFN-b-luciferase reporter construct. After 24 hr, cells were stimulated for 6 hr
vity.
ulated with 10 mM of the indicated CDN or 100 mg/ml DMXAA (E), or human
timulated with 10 mM and 50 mMof the indicated CDN or 100 mg/ml DMXAA (F).
relative normalized expression was determined by comparison with untreated
ell Reports 11, 1018–1030, May 19, 2015 ª2015 The Authors 1023
Figure 4. Synthetic CDN Modifications Sig-
nificantly Improve Anti-tumor Efficacy in
Established B16 Tumors
(A and B) WT C57BL/6 mice were inoculated with
53 104 B16.F10 cells in the left flank (n = 8). When
tumor volumes were 100 mm3, they received three
25 mg IT doses of ML CDA, ML CDG, ML RR-S2
CDG, ML RR-S2 CDA, or HBSS as control (A) or
either three 50 mg doses of the endogenous cGAS
product ML cGAMP, ML RR-S2 CDA, ML RR-S2
cGAMP, or HBSS as control (n = 8; B).
(C) WT C57BL/6 mice or STING/ mice were
treated with three IT doses of CDNMLRR-S2 CDA
(50 mg), murine type B CpG ODN 1668 (50 mg), or
HBSS vehicle control. Treatments were adminis-
tered on the days indicated by the arrows, and
tumor measurements were taken twice weekly.
Data are representative of at least two indepen-
dent experiments. Results are shown as mean
tumor volume ± SEM. **p < 0.01; ***p < 0.001. ns,
not significant.these mice demonstrated significantly higher overall survival
compared to mice treated with ML RR-S2 CDG (Figure S5A).
ML RR-S2 CDA also showed higher anti-tumor control than the
endogenous ML cGAMP (Figure 4B). Thus, ML RR-S2 CDA
was selected for advancement to clinical development.
To determine whether the CDN-induced anti-tumor efficacy
was STING-dependent, we compared activity in B16 tumor-
bearing WT (C57BL/6) and STING/ mice. CDN therapeutic ef-
ficacy was completely lost in STING/ mice. In contrast, a CpG
TLR9 agonist (Kawarada et al., 2001) did modestly reduce tumor
growth in STING/ mice, demonstrating that this mouse strain
is capable of mounting an immune-mediated antitumor res-
ponse (Figure 4C). A dose response of the ML RR-S2 CDA com-
pound was performed in B16 tumor-bearing mice, which
identified an optimal anti-tumor dose level that also elicited
maximum tumor antigen-specific CD8+ T cell responses (data
not shown) and improved long-term survival to 50% (Figures
S5B and S5C).
To evaluate which cell types are targeted by STING agonists in
the TME, we analyzed the expression of IFN-b after ML RR-S2
CDA or DMXAA stimulation in BM-DC, bone marrow-derived
macrophages, purified T cells from naive mice, B16 tumor cells,
mouse embryonic fibroblasts (MEFs), andmouse primary dermal
fibroblasts. Except for tumor cells, all cell types tested were
found to express IFN-b. However, expression in WT BM-DCs
was ten times higher than in the other cell types (Figure S5D).
To determine whether this was also the case in the TME, we
sorted four different cell populations from pre-established B16
tumors: DCs (CD45+ CD11c+ MHCII+), macrophages (CD45+
CD11b+ F4/80+ MHC-II+), T cells (CD45+ CD3+), and endothelial1024 Cell Reports 11, 1018–1030, May 19, 2015 ª2015 The Authorscells (CD45 CD31+). Sorted cells were
then stimulated ex vivo with ML RR-S2
CDA or DMXAA. All subsets expressed
IFN-b upon stimulation with the STING
agonists. Expression in macrophages
was highest, followed by DCs, which
were both higher as compared with lym-phocytes and endothelial cells (Figure S5E). These data demon-
strate that themain source of type I IFN in the TME is likely APCs,
although stromal cells and T cells might also contribute. Interest-
ingly and in agreement with these data, we observed that the
CD8a+/CD103+ DCs play a critical role in vivo, as the therapeutic
effect of DMXAA was significantly diminished in Batf3/ mice
(Figure S5F). Altogether, these findings suggest that CD8a+/
CD103+ DCs are critical for curative anti-tumor therapy by
STING agonists.
ML RR-S2 CDA Induces Lasting Immune-Mediated
Tumor Rejection in Multiple Tumor Types
To test anti-tumor efficacy in diverse tumor models, BALB/c
mice bearing established 4T1 colon or CT26 mammary carci-
nomas were treated with ML RR-S2 CDA. All treated animals
showed significant and durable tumor regression. Mice that
were cured of their primary tumor were completely resistant to
re-challenge when the same tumor cell line was used (Figures
5A and 5B). However, animals cured from CT26 tumors after
ML RR-S2 CDA treatment showed no protection when they
were re-challenged with the 4T1 tumor cells, demonstrating
specificity (Figure 5B). Increased T cell responses were
observed against the endogenous CT26 rejection antigen AH1
(Slansky et al., 2000) (Figure 5C). IT injection of ML RR-S2 CDA
into one tumor in BALB/c mice bearing bilateral CT26 or 4T1 tu-
mors also demonstrated significant regression of the contralat-
eral, untreated tumor (Figures 5D and S5G). Using a different
model to study the distal effect of ML RR-S2 CDA, we implanted
B16.F10 melanoma in C57BL/6 mice and 7 days later intrave-
nously infused B16.F10 melanoma cells to generate lung
metastases. The 2-week-old established flank tumors were
treated with ML RR-S2 CDA, DMXAA, or HBSS control, and
2 weeks later, lung metastases were enumerated. Mice treated
in the flank tumor with ML RR-S2 CDA showed substantial con-
trol of distant lung metastases (Figure 5E). Together, these
results demonstrate that IT injection with ML RR-S2 CDA eradi-
cates multiple tumor types and primes an effective systemic
CD8+ T cell immune response that significantly inhibits the
growth of distal, untreated lesions.
DISCUSSION
Our results indicate that IT administration of STING agonists
generates a potent anti-tumor immune T cell response and strik-
ing durable disease regression in multiple mouse tumor models.
Although DMXAA has a potent therapeutic effect in mice, it lacks
the ability to activate hSTING. The chemically modified CDN
compounds described here have the capacity to activate all hu-
man polymorphic STING molecules while retaining the ability to
engage mSTING and demonstrate a similarly impressive anti-tu-
mor effect. The participation of the adaptive immune response
for the observed anti-tumor responses is supported by the sec-
ondary rejection of non-injected tumors, the clearance of lung
metastases, and long-term immunologic memory observed
against autologous tumor re-challenge.
The mechanism of the therapeutic effect observed with the
compounds tested in this study was absolutely dependent on
host STING, and themajority of the anti-tumor effect was depen-
dent upon T cells, specifically CD8+ T cells, as described (Jassar
et al., 2005; Wallace et al., 2007). However, a partial therapeutic
effect was observed in RAG/ and TCRa/ mice, indicating
that innate immune cells are an important contributor to anti-tu-
mor efficacy. Our in vitro data show that the various synthetic
STING agonists tested induced IFN-b production by APCs via a
mechanism that depended on the classical STING-TBK1-IRF3
signaling pathway (Ishikawa et al., 2009). In addition, STING ag-
onists inducedproduction of other cytokines,DCmaturation, and
also chemokine production in vitro. Previous work characterizing
the vascular disrupting property of DMXAA demonstrated induc-
tion of TNF-a by stromal cells in vivo (Joseph et al., 1999) and
attenuation of the therapeutic effect in TNFR/ mice (Zhao
et al., 2002). Thus, the T-cell-independent component of the ther-
apeutic effect ofSTINGagonists in vivomaybemediated through
early TNF-a-mediated tumor vascular destruction. In addition, it
seems likely that the induction of chemokines by STING agonists
may also contribute to effectivemigration of activated T cells into
the TME within the injected tumor site. This multi-faceted mech-
anism of action may explain the therapeutic potency of STING
agonists against a range of cancers in vivo.
We developed synthetic CDN-derivative molecules based on
rationally designed STING structure-function relationships. The
lead molecule ML RR-S2 CDA has several features that improve
both stability and lipophilicity, promoting significantly increased
STING signaling as compared to endogenous and pathogen-
derived CDNs. Whereas canonical CDNs have been evaluated
as vaccine adjuvants and were recently shown to inhibit growth
of 4T-1 tumors when given by intraperitoneal injection (Chandra
et al., 2014), those investigations used canonical CDNs that mayCnot be appropriate for clinical development, because there are
hSTING alleles at significant frequencies in the population that
are refractory to these structures. In the present study, we
show the profound anti-tumor efficacy resulting from activation
of the STING pathway with synthetic CDNs that not only activate
all known hSTING alleles but have significantly higher potency
than the natural STING ligands generated by cGAS. Although
some human donors showed higher responsiveness to ML
cGAMP, such as the donor bearing the refractory reference allele
represented in Figure 3F, overall ML RR-S2 CDA activated all
known hSTING allelic variants. This compound will therefore
be attractive for clinical development.
A possible limitation of the treatment approach described
herein is the necessity for IT injection to achieve maximal thera-
peutic effect. However, a practical advantage of this strategy is
that it has the potential to generate T cell responses against
tumor-specific antigens expressed by a patient’s individual can-
cer. The attractiveness of IT injection approaches has been re-
kindled based on several recent clinical trial observations. IT
injection of the oncolytic virus T-VEC has been shown in a ran-
domized trial to provide improved clinical activity in melanoma
patients compared with control (Goins et al., 2014). In addition,
Levy and colleagues have shown that IT injection of the TLR9
agonist CpG along with local low-dose radiation therapy had
clinical activity in patients with non-Hodgkin’s lymphoma (Brody
et al., 2010). Both of these studies demonstrated regression of
non-injected lesions, consistent with the induction of tumor-spe-
cific T cells that could promote regression of tumors at distant
sites. These observations, along with the impressive potency
of STING agonists preclinically, support the development of
clinical strategies for IT injection of STING agonists as a cancer
therapeutic in patients.EXPERIMENTAL PROCEDURES
Cells and Cell Isolations
The cells used for the in vivo experiments were: the C57BL/6-derived
melanoma cell lines B16.F10 and B16.F10.SIY (henceforth referred to as
B16.SIY), the breast cancer 4T1 cell line, and the colon cancer CT26 cell lines,
all originally purchased from ATCC. All cells were maintained at 37C with 5%
CO2 in DMEM supplemented with 10% heat-inactivated FCS, penicillin,
streptomycin, L-arginine, L-glutamine, folic acid, and L-asparagine.
Immortalized WT and STING/ macrophages were obtained as described
in Roberson and Walker (1988). The WT macrophages were obtained from Dr.
K. Fitzgerald (University of Massachusetts). Non-immortalized macrophages
were derived from the bone marrow of WT (C57BL/6) or STING/ mice and
cultured in BMMmedia (RPMI media with 5% CSF, 5% FBS, 13 L-glutamine,
and 13 pen/strep) for 7 days prior to use. Human PBMCs were isolated by
density-gradient centrifugation using Ficoll-Paque Plus (GE Healthcare).
For stable overexpression of HA-STING in STING/macrophages, the full-
lengthmSting-HADNA sequencewas generated by PCR. Sequence encoding
full-length mSTING was amplified from pUNOI-mSTING plasmid (Invivogen)
using a 50 primer containing an EcoRI site, gcagacGAATTCATGCCATACTC
CAACCTGCATCCAGCCATCCCACGGCCCAGAGGTCACCGCTCCAAATAT
GTAGCCCTCATCTTTCTGGTGGCCAG, and a 30 primer containing the HA-
tag nucleotide sequence, followed by a TGA stop codon and a NotI site, tca
catGCGGCCGCTCAGGCGTAGTCAGGCACGTCGTAAGGATAGATGAGGTC
AGTGCGGAGTGGGAGAGGCTGATCC. The mSTING-HA PCR product was
gel purified and double digested with EcoRI and NotI and then cloned into
the multiple cloning site of pMXS-IRES-GFP with Quick ligation kit (New
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Figure 5. ML RR-S2 CDA Promotes Immune-Mediated Tumor Rejection
(A and B)WTBALB/cmicewere inoculated with 105 4T-1 breast cancer (A) or CT26 (B) colon carcinoma cells in the left flank.When tumor volumeswere 100mm3,
they received three 50 mg doses IT ofMLRR-S2CDA or HBSS vehicle control (left graph). Micewere re-implantedwith 105 4T1 (A andB) or CT26 (B) tumor cells on
the opposite flank on day 55 post-initial tumor implantation. Naive mice were used as controls (right graph; n = 8).
(C) WT BALB/c mice were inoculated with 105 CT26 colon carcinoma cells in the left flank and treated on days 11, 14, and 18 with IT injections of ML RR-S2 CDA
(25 mg each) or HBSS vehicle control (n = 4). 21 days post-implantation of CT26 tumors, PBMCs were stimulated with AH1 (gp70423-431) and assessed by IFN-g
ELISPOT assay.
(legend continued on next page)
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Stable HEK293T STING-expressing cell lines were generated with MSCV2.2
retroviral plasmids that contain STING cDNA cloned upstream of an IRES
in frame with GFP. hSTING(REF)-HA, hSTING(WT)-HA, hSTING(HAQ)-HA,
hSTING(Q)-HA, and mSTING(WT)-HA retroviral plasmids were obtained from
the Vance Laboratory at UC Berkeley. hSTING(AQ)-HA was derived from
hSTING(Q)-HA using a QuickChange Site-Directed Mutagenesis kit (Strata-
gene). Retroviral vectors were transfected into the amphotropic Phoenix pack-
aging cell line using Lipofectamine (Invitrogen). After 2 days, viral supernatants
were harvested and used for transduction of STING/ macrophages or
HEK293T cells. GFP+ cells were sorted in FACSAria (BD Bioscience) or
MoFlow cell sorters.
Protein Expression and Purification
STING ligand-binding domains (human amino acids [aas] 140–379; mouse aas
139–378) were cloned via ligation-independent cloning into a custom pET-
based vector containing a 6xHIS-SUMO-tobacco etch virus protease (TEV)
site. All plasmids were confirmed by sequencing. Proteins were expressed in
BL21 DE3 Rosetta 2 cells (EMD Millipore). Cells were grown in LB media at
37C until an OD600 of about 0.6. Cells were then shifted to 18C, induced
with 0.25 mM isopropyl-beta-D-thiogalactopyranoside, and grown for 18–
20 hr. Fusion proteins were purified on Ni-NTA agarose (QIAGEN). The
6xHIS-SUMO tagwas removed by digestionwith TEV protease (SigmaAldrich)
overnight during dialysis against buffer containing 20 mM Tris-HCl, 150 mM
NaCl, 5 mM imidazole, 10% glycerol, and 0.5 mM Tris (2-carboxyethyl) phos-
phine (pH 7.5). After dialysis, the 6xHIS-SUMO tag and TEV protease were
removed by Ni-NTA agarose. Proteins were concentrated to between 9 and
13 mg/ml. Aliquots were flash frozen in liquid nitrogen and stored at 80C.
ImageStream Analysis of STING Aggregation in Cells
STING/ macrophages overexpressing STING-HA tag were stimulated for
1 hr with 50 mg/ml of DMXAA resuspended in 7.5% of NaHCO3, 50 mM of
ML RR-S2 CDA resuspended in HBSS, or only the vehicles as control. After
the incubation, cells were stained with anti-CD11b-APC (M1/70; BioLegend),
rabbit anti-HA-tag (C29F4; Cell Signaling) and anti-rabbit IgG-PE (Invitrogen),
and DAPI (Invitrogen). Single cell images were acquired in the ImageStreamx
Mark II (Amnis), and data were analyzed using IDEAS software.
Western Blot Analysis
WT, STING/ macrophages, and STING/ macrophages overexpressing
STING-HA or an empty vector were stimulated with 50 mg/ml DMXAA for 0,
15, 60, or 180 min; BM-DCs from WT or STING/ mice were stimulated
with 25 mg/ml DMXAA for the same time points. Proteins were extracted
with Triton-X100 buffer (150 mM sodium chloride, 50 mM Tris, 1% Triton-
X100 [pH 8.0]) with proteinase inhibitors (Thermo Scientific) and phosphatase
inhibitors (Sigma). 30 mg of protein was electrophoresed in 10% SDS-PAGE
gels and transferred onto Immobilon-FL membranes (Millipore). Blots were
incubated with antibodies specific for phosphorylated TBK1 (Ser172), phos-
phorylated IRF3 (Ser396), total TBK1, STING, and GAPDH (Cell Signaling) or
total IRF3 (Invitrogen). Proteins from HEK293T lines stably expressing STING
were extracted with M-PER (Thermo Scientific). 6 mg of protein was loaded
onto a 4–12% MES NuPAGE gel (Life Technologies), transferred to nitrocellu-
lose, and probed with anti-HA antibody (Santa Cruz Biotechnology). Anti-rab-
bit IRDye 680RD label secondary antibody was used for visualization of bands
with the Odyssey Imaging system (LI-COR Biosciences).
Differential Scanning Fluorimetry
Thermal shift assays were performed as in Cavlar et al. (2013). Assays were
conducted with STING ligand binding domain at 1 mg/ml with or without(D) WT BALB/c mice were implanted with 105 of CT26 tumor cells on both flanks.
(50 mg) or HBSS vehicle control (n = 8).
(E) WT C57BL/6 were inoculated with 5 3 104 B16.F10 melanoma cells on the r
implanted with cells i.v. only as a control. Flank tumors were treated on the days in
On day 28, lungs were harvested and lung tumor nodules counted. The histogra
control-treatedmice, compared to the untreated i.v.-only tumor implantedmice. T
representative of at least two independent experiments. Results are shown as m
Cvarious CDNs at 1 mM in 20 mM Tris-HCl, 150 mM NaCl (pH 7.5), and 1:500
dilution of SYPRO Orange Dye (Life Technologies). The fluorescence as a
function of temperature was recorded in a CFX 96 real-time PCR machine
(Bio-Rad) reading on the HEX channel EX 450–490 EM 560–580 nm. The tem-
perature gradient was from 15C to 80C, ramping 0.5Cper 15 s. Curveswere
fit to a Boltzmann sigmoidal (Graph Pad Prism) to establish the midpoint of
thermal unfolding (Tm).
Murine IFN-b ELISA
WT or STING/ macrophages and BM-DCs from WT or STING/ mice were
stimulatedwith 50 mg/ml DMXAA. Conditionedmedia were collected after 4 hr.
IFN-b concentration was assessed using VeriKine Mouse Interferon Beta
ELISA Kit (PBL interferon source).
qRT-PCR Analysis of Cytokines
BM-DCs fromWT or STING/mice were stimulated with 25 mg/ml DMXAA or
100 ng/ml LPS for 4 hr. Total RNA was isolated using the RNeasy kit (QIAGEN)
and incubated with DNase I, Amplification Grade (Invitrogen). cDNA was syn-
thesized using High Capacity cDNA Reverse Transcription Kit (Applied Bio-
systems), expression of cytokines was measured by real-time qRT-PCR using
specific primers/probes for mouse INF-b, TNF-a, IL-6, and IL12p40, and pan-
specific primers were to quantify expression of the IFN-a family. Primer se-
quences are listed in Table S1 in Supplemental Information. PCR reactions
were performed in the 7300 Real Time PCR system (Applied Biosystems).
The results are expressed as 2DCt using 18S as endogenous control.
WT BMM was stimulated with CDN at 5 mM in HBSS with the addition of Ef-
fectene (QIAGEN) transfection reagent (per kit protocol). Human PBMCs were
stimulated as indicated. Stimulated cells were assessed by real-time qRT-
PCR for gene expression of IFN-b1, MCP-1, TNF-a, and IL-6 using the
PrimePCR RNA purification, and cDNA analysis system, and run on the
CFX96 gene cycler (Bio-Rad). Relative normalized expression was determined
by comparing induced target gene expression to unstimulated controls, using
the reference genesGapdh and Ywhaz (mouse) andGUSBandPGK1 (human),
genes confirmed to have a coefficient variable (CV) below 0.5 and M value
below 1, and thus did not vary with different treatment conditions.
Mice
All animals were used according to protocols approved by Institutional Animal
Use Committee of the University of Chicago and Aduro Biotech and main-
tained in pathogen-free conditions in a barrier facility. C57BL/6, BALB/c,
C3H/He, and TCRa/ mice were obtained from Jackson and Charles River.
RAG2/ mice were obtained from Taconic. Tmem173/ (STING-deficient)
mice were provided by Dr. G. Barber (University of Miami), and STING/
(Goldenticket; Sauer et al., 2011) and IFNAR/ mice were purchased from
Jackson Laboratories. Batf3/micewere provided byDr. KennethM.Murphy
(Washington University School of Medicine).
In Vivo Tumor Experiments
106 of B16-SIY tumor cells, 53 104 B16.F10 tumor cells, 105 4T1 and CT26, or
106 other tumor cells were injected s.c. in 100 ml DPBS or HBSS on the right
flank of mice. Following tumor implantation, mice were randomized into treat-
ment groups. When tumors were 100–200 mm3 in volume (5–7 mm wide),
either one single or three doses of DMXAA resuspended in 7.5% of NaHCO3
or CDNs formulated in HBSS or vehicle control were injected IT. Measure-
ments of tumors were performed twice per week using calipers, and the tumor
volumewas calculated with the formula V = (length3width2)/2. In some exper-
iments, tumor-free survivors were re-challenged with tumor cells on the oppo-
site flank several weeks after the injection of the primary tumor. Naive miceOn the days indicated, mice were treated in one flank only with ML RR-S2 CDA
ight flank at day 0 and implanted i.v. with 105 cells on day 7. Naive mice were
dicated with ML RR-S2 CDA (50 mg), DMXAA (150 mg), or HBSS control (n = 8).
m depicts total numbers of nodules in the ML RR-S2 CDA, DMXAA, or HBSS-
he images depict theMLRR-S2 CDA andHBSS-control-treatedmice. Data are
ean ± SEM. **p < 0.01; ***p < 0.001.
ell Reports 11, 1018–1030, May 19, 2015 ª2015 The Authors 1027
were used as controls. For the contralateral experiments, mice were implanted
on both flanks and only one tumor was treated. For the B16 melanoma lung
metastasis experiments, mice were implanted on the flank with 5 3 104 cells
B16.F10 on day 0 and then injected intravenously with 1 3 105 cells on
day 7. Lungs were harvested on day 28. Administration of compounds, mea-
surements of tumors, and counting of lung tumors were performed in a blinded
fashion.
IFN-g ELISPOT and SIY-Pentamer Staining
Splenocytes were analyzed 5 days after the first IT injection of DMXAA or ML
RR-S2CDA. For the ELISPOTs, 106 splenocyteswere plated per well and stim-
ulated overnight with SIY peptide (160 nM) or AH1 (1 mM) peptide, with PMA
(50 ng/ml) plus ionomycin (0.5 mM) as a positive control or medium as negative
control. Spots were developed using the BD mouse IFN-g kit according to the
manufacturer’s instructions, and the number of spots was measured using an
Immunospot Series 3 Analyzer and analyzed using ImmunoSpot software
(Cellular Technology). For SIY-pentamer staining, splenocytes were preincu-
bated for 15minwith anti-CD16/32monoclonal antibody (93) to block potential
nonspecific binding and labeled with PE-MHC class I pentamer (Proimmune)
consisting of murine H-2Kb complexed to SIYRYYGL (SIY) peptide, anti-
TCRb-AF700 (H57-597), anti-CD8-Pacific Blue (53-6.7), anti-CD4-Pacific
Orange (RM4-5) (all antibodies from BioLegend), and the Fixable Viability
Dye eFluor 450 (eBioscience). Stained cells were analyzed using LSR II cytom-
eter with FACSDiva software (BD Biosciences). Data analysis was conducted
with FlowJo software (Tree Star).
Luciferase Assay
104 HEK293T cells were seeded in 96-well plates and transiently transfected
(Lipofectamine 2000) with human IFN-b firefly reporter plasmid (Fitzgerald
et al., 2003) and TK-Renilla luciferase reporter for normalization. The following
day, cells were stimulated with 10 mMof each CDN or 100 mg/ml DMXAA using
digitonin permeabilization (50mMHEPES, 100mMKCL, 3 mMMgCl2, 0.1 mM
DTT, 85 mM sucrose, 0.2% BSA, 1 mM ATP, 0.1 mM GTP, and 10 mg/ml digi-
tonin) to ensure uniform uptake. After 20 min, stimulation mixtures were
removed and normal media was added. After a total of 6 hr, cell lysates
were prepared and reporter gene activity measured using the Dual Luciferase
Assay System (Promega) on a Spectramax M3 luminometer.
Statistical Analysis
Student’s paired t test was used to calculate two-tailed p values to estimate
statistical significance of differences between two treatment groups using
Prism 6 software. The number ofmice per group and the statistically significant
p values are labeled in the figures and/or legends with asterisks.
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Supplemental Information includes Supplemental Experimental Procedures,
five figures, and one table and can be found with this article online at http://
dx.doi.org/10.1016/j.celrep.2015.04.031.
AUTHOR CONTRIBUTIONS
L.C., L.H.G., T.W.D., and T.F.G. conceived the research and conducted the
experiments with S.M.M., D.B.K., K.E.S., E.L., J.J.L., G.E.K., T.B., S.-R.W.,
and K.M. T.W.D., and T.F.G. conceived and supervised the entire project
and wrote and revised the manuscript with L.C., L.H.G., K.E.S., and S.M.M.
ACKNOWLEDGMENTS
We thank Meredith Leong, Pete Lauer, and Russell Vance for discussions;
Jake Bruml, Ryan Duggan, Michael Y.K. Leung, and Diana Ranoa for technical
assistance; and Elie Diner for retroviral constructs. We thank Hector Nolla at
the UC Berkeley Cancer Research Laboratory (CRL) for help with cell sorting.
L.C. was supported by a post-doctoral fellowship from the Ramon Areces
Foundation. This work was supported by P01 CA97296 and R01CA181160
from the National Cancer Institute. L.H.G., S.M.M., D.B.K., K.E.S., G.E.K.,1028 Cell Reports 11, 1018–1030, May 19, 2015 ª2015 The AuthorsE.L, T.B., J.J.L., K.M., and T.W.D. are all paid employees of Aduro BioTech,
hold stock in the company, and may be inventors on patent applications
that apply to the CDN molecules described in the manuscript.
Received: November 26, 2014
Revised: February 24, 2015
Accepted: April 14, 2015
Published: May 7, 2015
REFERENCES
Ablasser, A., Goldeck, M., Cavlar, T., Deimling, T., Witte, G., Ro¨hl, I., Hopfner,
K.P., Ludwig, J., and Hornung, V. (2013). cGAS produces a 20-50-linked cyclic
dinucleotide second messenger that activates STING. Nature 498, 380–384.
Baguley, B.C., and Ching, L.-M. (1997). Immunomodulatory actions of xanthe-
none anticancer agents. BioDrugs 8, 119–127.
Blank, C., Brown, I., Peterson, A.C., Spiotto, M., Iwai, Y., Honjo, T., andGajew-
ski, T.F. (2004). PD-L1/B7H-1 inhibits the effector phase of tumor rejection by
T cell receptor (TCR) transgenic CD8+ T cells. Cancer Res. 64, 1140–1145.
Brody, J.D., Ai, W.Z., Czerwinski, D.K., Torchia, J.A., Levy, M., Advani, R.H.,
Kim, Y.H., Hoppe, R.T., Knox, S.J., Shin, L.K., et al. (2010). In situ vaccination
with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study.
J. Clin. Oncol. 28, 4324–4332.
Burdette, D.L., and Vance, R.E. (2013). STING and the innate immune
response to nucleic acids in the cytosol. Nat. Immunol. 14, 19–26.
Burdette, D.L., Monroe, K.M., Sotelo-Troha, K., Iwig, J.S., Eckert, B., Hyodo,
M., Hayakawa, Y., and Vance, R.E. (2011). STING is a direct innate immune
sensor of cyclic di-GMP. Nature 478, 515–518.
Cavlar, T., Deimling, T., Ablasser, A., Hopfner, K.P., and Hornung, V. (2013).
Species-specific detection of the antiviral small-molecule compound CMA
by STING. EMBO J. 32, 1440–1450.
Chandra, D., Quispe-Tintaya, W., Jahangir, A., Asafu-Adjei, D., Ramos, I., Sin-
tim, H.O., Zhou, J., Hayakawa, Y., Karaolis, D.K., and Gravekamp, C. (2014).
STING ligand c-di-GMP improves cancer vaccination against metastatic
breast cancer. Cancer Immunol Res 2, 901–910.
Conlon, J., Burdette, D.L., Sharma, S., Bhat, N., Thompson, M., Jiang, Z., Ra-
thinam, V.A.K., Monks, B., Jin, T., Xiao, T.S., et al. (2013). Mouse, but not hu-
man STING, binds and signals in response to the vascular disrupting agent
5,6-dimethylxanthenone-4-acetic acid. J. Immunol. 190, 5216–5225.
Deng, L., Liang, H., Xu, M., Yang, X., Burnette, B., Arina, A., Li, X.-D., Mauceri,
H., Beckett, M., Darga, T., et al. (2014). STING-dependent cytosolic DNA
sensing promotes radiation-induced type I interferon-dependent antitumor im-
munity in immunogenic tumors. Immunity 41, 843–852.
Diamond, M.S., Kinder, M., Matsushita, H., Mashayekhi, M., Dunn, G.P., Arch-
ambault, J.M., Lee, H., Arthur, C.D., White, J.M., Kalinke, U., et al. (2011). Type
I interferon is selectively required by dendritic cells for immune rejection of tu-
mors. J. Exp. Med. 208, 1989–2003.
Diner, E.J., Burdette, D.L., Wilson, S.C., Monroe, K.M., Kellenberger, C.A., Hy-
odo, M., Hayakawa, Y., Hammond, M.C., and Vance, R.E. (2013). The innate
immune DNA sensor cGAS produces a noncanonical cyclic dinucleotide that
activates human STING. Cell Rep. 3, 1355–1361.
Dubensky, T.W., Jr., Kanne, D.B., and Leong, M.L. (2013). Rationale, progress
and development of vaccines utilizing STING-activating cyclic dinucleotide
adjuvants. Ther Adv Vaccines 1, 131–143.
Ebensen, T., Schulze, K., Riese, P., Link, C., Morr, M., and Guzma´n, C.A.
(2007a). The bacterial second messenger cyclic diGMP exhibits potent adju-
vant properties. Vaccine 25, 1464–1469.
Ebensen, T., Schulze, K., Riese, P., Morr, M., and Guzma´n, C.A. (2007b). The
bacterial second messenger cdiGMP exhibits promising activity as a mucosal
adjuvant. Clin. Vaccine Immunol. 14, 952–958.
Ebensen, T., Libanova, R., Schulze, K., Yevsa, T., Morr, M., and Guzma´n, C.A.
(2011). Bis-(30,50)-cyclic dimeric adenosine monophosphate: strong Th1/Th2/
Th17 promoting mucosal adjuvant. Vaccine 29, 5210–5220.
Fitzgerald, K.A., McWhirter, S.M., Faia, K.L., Rowe, D.C., Latz, E., Golenbock,
D.T., Coyle, A.J., Liao, S.M., and Maniatis, T. (2003). IKKepsilon and TBK1 are
essential components of the IRF3 signaling pathway. Nat. Immunol. 4,
491–496.
Fuertes, M.B., Kacha, A.K., Kline, J., Woo, S.R., Kranz, D.M., Murphy, K.M.,
and Gajewski, T.F. (2011). Host type I IFN signals are required for antitumor
CD8+ T cell responses through CD8alpha+ dendritic cells. J. Exp. Med. 208,
2005–2016.
Gaffney, B.L., Veliath, E., Zhao, J., and Jones, R.A. (2010). One-flask synthe-
ses of c-di-GMP and the [Rp,Rp] and [Rp,Sp] thiophosphate analogues. Org.
Lett. 12, 3269–3271.
Gajewski, T.F., Woo, S.R., Zha, Y., Spaapen, R., Zheng, Y., Corrales, L., and
Spranger, S. (2013). Cancer immunotherapy strategies based on overcoming
barriers within the tumor microenvironment. Curr. Opin. Immunol. 25, 268–
276.
Galon, J., Page`s, F., Marincola, F.M., Angell, H.K., Thurin, M., Lugli, A., Zlobec,
I., Berger, A., Bifulco, C., Botti, G., et al. (2012). Cancer classification using the
Immunoscore: a worldwide task force. J. Transl. Med. 10, 205.
Gao, P., Ascano, M., Zillinger, T., Wang, W., Dai, P., Serganov, A.A., Gaffney,
B.L., Shuman, S., Jones, R.A., Deng, L., et al. (2013a). Structure-function anal-
ysis of STING activation by c[G(20,50)pA(30,50)p] and targeting by antiviral
DMXAA. Cell 154, 748–762.
Gao, P., Ascano,M., Wu, Y., Barchet, W., Gaffney, B.L., Zillinger, T., Serganov,
A.A., Liu, Y., Jones, R.A., Hartmann, G., et al. (2013b). Cyclic [G(20,50)pA(30,50)
p] is the metazoan second messenger produced by DNA-activated cyclic
GMP-AMP synthase. Cell 153, 1094–1107.
Goins, W.F., Huang, S., Cohen, J.B., and Glorioso, J.C. (2014). Engineering
HSV-1 vectors for gene therapy. Methods Mol. Biol. 1144, 63–79.
Gray, P.M., Forrest, G., Wisniewski, T., Porter, G., Freed, D.C., DeMartino,
J.A., Zaller, D.M., Guo, Z., Leone, J., Fu, T.M., and Vora, K.A. (2012). Evidence
for cyclic diguanylate as a vaccine adjuvant with novel immunostimulatory ac-
tivities. Cell. Immunol. 278, 113–119.
Harlin, H., Meng, Y., Peterson, A.C., Zha, Y., Tretiakova, M., Slingluff, C.,
McKee, M., and Gajewski, T.F. (2009). Chemokine expression in melanoma
metastases associated with CD8+ T-cell recruitment. Cancer Res. 69, 3077–
3085.
Hildner, K., Edelson, B.T., Purtha, W.E., Diamond, M., Matsushita, H., Ko-
hyama, M., Calderon, B., Schraml, B.U., Unanue, E.R., Diamond, M.S., et al.
(2008). Batf3 deficiency reveals a critical role for CD8alpha+ dendritic cells
in cytotoxic T cell immunity. Science 322, 1097–1100.
Ishikawa, H., and Barber, G.N. (2008). STING is an endoplasmic reticulum
adaptor that facilitates innate immune signalling. Nature 455, 674–678.
Ishikawa, H., Ma, Z., and Barber, G.N. (2009). STING regulates intracellular
DNA-mediated, type I interferon-dependent innate immunity. Nature 461,
788–792.
Jassar, A.S., Suzuki, E., Kapoor, V., Sun, J., Silverberg, M.B., Cheung, L., Bur-
dick, M.D., Strieter, R.M., Ching, L.M., Kaiser, L.R., and Albelda, S.M. (2005).
Activation of tumor-associated macrophages by the vascular disrupting agent
5,6-dimethylxanthenone-4-acetic acid induces an effective CD8+ T-cell-medi-
ated antitumor immune response in murine models of lung cancer and meso-
thelioma. Cancer Res. 65, 11752–11761.
Jin, L., Xu, L.G., Yang, I.V., Davidson, E.J., Schwartz, D.A., Wurfel, M.M., and
Cambier, J.C. (2011). Identification and characterization of a loss-of-function
human MPYS variant. Genes Immun. 12, 263–269.
Joseph, W.R., Cao, Z., Mountjoy, K.G., Marshall, E.S., Baguley, B.C., and
Ching, L.M. (1999). Stimulation of tumors to synthesize tumor necrosis fac-
tor-alpha in situ using 5,6-dimethylxanthenone-4-acetic acid: a novel
approach to cancer therapy. Cancer Res. 59, 633–638.
Kawarada, Y., Ganss, R., Garbi, N., Sacher, T., Arnold, B., andHa¨mmerling, G.J.
(2001). NK- and CD8(+) T cell-mediated eradication of established tumors by
peritumoral injection of CpG-containing oligodeoxynucleotides. J. Immunol.
167, 5247–5253.CKim, S., Li, L., Maliga, Z., Yin, Q.,Wu, H., andMitchison, T.J. (2013). Anticancer
flavonoids are mouse-selective STING agonists. ACS Chem. Biol. 8, 1396–
1401.
Konno, H., Konno, K., and Barber, G.N. (2013). Cyclic dinucleotides trigger
ULK1 (ATG1) phosphorylation of STING to prevent sustained innate immune
signaling. Cell 155, 688–698.
Lara, P.N., Jr., Douillard, J.Y., Nakagawa, K., von Pawel, J., McKeage, M.J.,
Albert, I., Losonczy, G., Reck, M., Heo, D.S., Fan, X., et al. (2011). Randomized
phase III placebo-controlled trial of carboplatin and paclitaxel with or without
the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell
lung cancer. J. Clin. Oncol. 29, 2965–2971.
Li, L., Yin, Q., Kuss, P., Maliga, Z., Milla´n, J.L., Wu, H., and Mitchison, T.J.
(2014). Hydrolysis of 2’30-cGAMP by ENPP1 and design of nonhydrolyzable
analogs. Nat. Chem. Biol. 10, 1043–1048.
McWhirter, S.M., Barbalat, R., Monroe, K.M., Fontana, M.F., Hyodo, M.,
Joncker, N.T., Ishii, K.J., Akira, S., Colonna, M., Chen, Z.J., et al. (2009). A
host type I interferon response is induced by cytosolic sensing of the bacterial
second messenger cyclic-di-GMP. J. Exp. Med. 206, 1899–1911.
Niesen, F.H., Berglund, H., and Vedadi, M. (2007). The use of differential scan-
ning fluorimetry to detect ligand interactions that promote protein stability.
Nat. Protoc. 2, 2212–2221.
Postow, M.A., Harding, J., and Wolchok, J.D. (2012). Targeting immune
checkpoints: releasing the restraints on anti-tumor immunity for patients
with melanoma. Cancer J. 18, 153–159.
Prantner, D., Perkins, D.J., Lai, W.,Williams,M.S., Sharma, S., Fitzgerald, K.A.,
and Vogel, S.N. (2012). 5,6-Dimethylxanthenone-4-acetic acid (DMXAA) acti-
vates stimulator of interferon gene (STING)-dependent innate immune path-
ways and is regulated by mitochondrial membrane potential. J. Biol. Chem.
287, 39776–39788.
Roberson, S.M., and Walker, W.S. (1988). Immortalization of cloned mouse
splenic macrophages with a retrovirus containing the v-raf/mil and v-myc on-
cogenes. Cell. Immunol. 116, 341–351.
Ro¨mling, U., Galperin, M.Y., and Gomelsky, M. (2013). Cyclic di-GMP: the first
25 years of a universal bacterial second messenger. Microbiol. Mol. Biol. Rev.
77, 1–52.
Sauer, J.D., Sotelo-Troha, K., von Moltke, J., Monroe, K.M., Rae, C.S., Bru-
baker, S.W., Hyodo, M., Hayakawa, Y., Woodward, J.J., Portnoy, D.A., and
Vance, R.E. (2011). The N-ethyl-N-nitrosourea-induced Goldenticket mouse
mutant reveals an essential function of Sting in the in vivo interferon response
to Listeria monocytogenes and cyclic dinucleotides. Infect. Immun. 79, 688–
694.
Slansky, J.E., Rattis, F.M., Boyd, L.F., Fahmy, T., Jaffee, E.M., Schneck, J.P.,
Margulies, D.H., and Pardoll, D.M. (2000). Enhanced antigen-specific anti-
tumor immunity with altered peptide ligands that stabilize the MHC-peptide-
TCR complex. Immunity 13, 529–538.
Sun, L., Wu, J., Du, F., Chen, X., and Chen, Z.J. (2013). Cyclic GMP-AMP syn-
thase is a cytosolic DNA sensor that activates the type I interferon pathway.
Science 339, 786–791.
Wallace, A., LaRosa, D.F., Kapoor, V., Sun, J., Cheng, G., Jassar, A., Blouin,
A., Ching, L.M., and Albelda, S.M. (2007). The vascular disrupting agent,
DMXAA, directly activates dendritic cells through a MyD88-independent
mechanism and generates antitumor cytotoxic T lymphocytes. Cancer Res.
67, 7011–7019.
Wolchok, J.D., Kluger, H., Callahan, M.K., Postow, M.A., Rizvi, N.A., Lesokhin,
A.M., Segal, N.H., Ariyan, C.E., Gordon, R.A., Reed, K., et al. (2013). Nivolu-
mab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 369, 122–133.
Woo, S.R., Fuertes, M.B., Corrales, L., Spranger, S., Furdyna, M.J., Leung,
M.Y., Duggan, R., Wang, Y., Barber, G.N., Fitzgerald, K.A., et al. (2014).
STING-dependent cytosolic DNA sensing mediates innate immune recogni-
tion of immunogenic tumors. Immunity 41, 830–842.
Woodward, J.J., Iavarone, A.T., and Portnoy, D.A. (2010). c-di-AMP secreted
by intracellular Listeria monocytogenes activates a host type I interferon
response. Science 328, 1703–1705.ell Reports 11, 1018–1030, May 19, 2015 ª2015 The Authors 1029
Yan, H., Wang, X., KuoLee, R., and Chen, W. (2008). Synthesis and immunos-
timulatory properties of the phosphorothioate analogues of cdiGMP. Bioorg.
Med. Chem. Lett. 18, 5631–5634.
Yi, G., Brendel, V.P., Shu, C., Li, P., Palanathan, S., and Cheng Kao, C. (2013).
Single nucleotide polymorphisms of human STING can affect innate immune
response to cyclic dinucleotides. PLoS ONE 8, e77846.1030 Cell Reports 11, 1018–1030, May 19, 2015 ª2015 The AuthorsZhang, X., Shi, H., Wu, J., Zhang, X., Sun, L., Chen, C., and Chen, Z.J. (2013).
Cyclic GMP-AMP containing mixed phosphodiester linkages is an endoge-
nous high-affinity ligand for STING. Mol. Cell 51, 226–235.
Zhao, L., Ching, L.M., Kestell, P., and Baguley, B.C. (2002). The antitumour ac-
tivity of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF receptor-1
knockout mice. Br. J. Cancer 87, 465–470.
